Type 2 Diabetes Clinical Trial
Official title:
Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes CTMS 20-0042
Verified date | June 2024 |
Source | The University of Texas Health Science Center at San Antonio |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study team will examine the effect of a ketogenic diet alone and ketogenic diet supplemented with oral ketones on how the body of individuals with type 2 diabetes respond to insulin, regulates insulin secretion, food intake and energetic pathways and influences body fat distribution.
Status | Completed |
Enrollment | 35 |
Est. completion date | April 25, 2023 |
Est. primary completion date | April 25, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Age from 18-70 years 2. BMI = 27.5-42 kg.m2 3. HbA1c = 7.0-10.5 4. Weight stable (±4-5lb) in the preceding 3 months 5. Good general health Exclusion Criteria: 1. Use of medications that affect glucose tolerance other than metformin/sulfonylurea/DPP4 Inhibitor 2. Major organ disease 3. Estimated Glomerular filtration rate (eGFR) <60 ml/min 4. Type 1 diabetes 5. Hematocrit < 34 (if HbA1c is in the 8.5 to 10% range) |
Country | Name | City | State |
---|---|---|---|
United States | University Health Systems-Texas Diabetes Institute | San Antonio | Texas |
United States | University of Texas Health Science Center at San Antonio | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center at San Antonio |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fasting plasma glucose (FPG) | A change in FPG will be measured | Baseline to 10 days | |
Primary | Hepatic Glucose production (HGP) | Change of hepatic glucose production will be measured using 3H-glucose infusion | Baseline to 10 days | |
Primary | Whole Body Fat Oxidation | Change in whole body fat oxidation will be measured using indirect calorimetry | Baseline to 10 days | |
Primary | Total Body Fat | Change in whole body fat | Baseline to 10 days | |
Primary | Hepatic Fat Content | Change in hepatic fat content | Baseline to 10 days | |
Secondary | Plasma Insulin | Change in plasma insulin will be measured | Baseline to 10 days | |
Secondary | C-peptide | Change in C-peptide will be measured | Baseline to 10 days | |
Secondary | Free Fatty Acid (FFA) | Change in FFA will be measured | Baseline to 10 days | |
Secondary | Glycerol level | Change in Glycerol level will be measured | Baseline to 10 days | |
Secondary | Low density lipoproteins (LDL) | Change in LDL | Baseline to 10 days | |
Secondary | High density lipoproteins (HDL) | Change in HDL | Baseline to 10 days | |
Secondary | Triglycerides | Change in triglyceride levels | Baseline to 10 days | |
Secondary | Urine Microalbumin excretion | Change in urine microalbumin excretion | Baseline to 10 days | |
Secondary | Glycated hemoglobin test (HbA1c) | Change in HbA1c | Baseline to 10 days | |
Secondary | Fructosamine level | Change in fructosamine | Baseline to 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |